Title is extremely misleading. It is starting a funding round, it has not received the funding as the title states. After Theranos I would expect any rational

Title is extremely misleading. It is starting a funding round, it has not received the funding as the title states. After Theranos I would expect any rational investor to approach this with extreme caution.